Search Results - Adam V. Patterson

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy by Zhe Fu, Alexandra M. Mowday, Jeff B. Smaill, Ian F. Hermans, Adam V. Patterson

    Published in Cells (2021-04-01)
    Get full text
    Article


  2. 2

    Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials by Linda Spiegelberg, Ruud Houben, Raymon Niemans, Dirk de Ruysscher, Ala Yaromina, Jan Theys, Christopher P. Guise, Jeffrey B. Smaill, Adam V. Patterson, Philippe Lambin, Ludwig J. Dubois

    Get full text
    Article


  3. 3

    Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents by Ziad Omran, Chris P. Guise, Linwei Chen, Cyril Rauch, Ashraf N. Abdalla, Omeima Abdullah, Ikhlas A. Sindi, Peter M. Fischer, Jeff B. Smaill, Adam V. Patterson, Yuxiu Liu, Qingmin Wang

    Published in Molecules (2021-06-01)
    Get full text
    Article


  4. 4

    Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications by Amir Ashoorzadeh, Alexandra M. Mowday, Christopher P. Guise, Shevan Silva, Matthew R. Bull, Maria R. Abbattista, Janine N. Copp, Elsie M. Williams, David F. Ackerley, Adam V. Patterson, Jeff B. Smaill

    Published in Pharmaceuticals (2022-02-01)
    Get full text
    Article


  5. 5

    Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity by Chris P. Guise, Maria R. Abbattista, Robert F. Anderson, Dan Li, Rana Taghipouran, Angela Tsai, Su Jung Lee, Jeff B. Smaill, William A. Denny, Michael P. Hay, William R. Wilson, Kevin O. Hicks, Adam V. Patterson

    Published in Molecules (2020-10-01)
    Get full text
    Article


  6. 6

    Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3 by Maria R. Abbattista, Amir Ashoorzadeh, Christopher P. Guise, Alexandra M. Mowday, Rituparna Mittra, Shevan Silva, Kevin O. Hicks, Matthew R. Bull, Victoria Jackson-Patel, Xiaojing Lin, Gareth A. Prosser, Neil K. Lambie, Gabi U. Dachs, David F. Ackerley, Jeff B. Smaill, Adam V. Patterson

    Published in Pharmaceuticals (2021-11-01)
    Get full text
    Article


  7. 7

    The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia by Cara E. Toscan, Hannah McCalmont, Amir Ashoorzadeh, Xiaojing Lin, Zhe Fu, Louise Doculara, Hansen J. Kosasih, Roxanne Cadiz, Anthony Zhou, Sarah Williams, Kathryn Evans, Faezeh Khalili, Ruilin Cai, Kristy L. Yeats, Andrew J. Gifford, Russell Pickford, Chelsea Mayoh, Jinhan Xie, Michelle J. Henderson, Toby N. Trahair, Adam V. Patterson, Jeff B. Smaill, Charles E. de Bock, Richard B. Lock

    Published in Blood Cancer Journal (2024-11-01)
    Get full text
    Article


Search Tools: